Does it run in the family? Toolkit will soon be available at federal health centers nationwide
, Genetic Alliance, June 2New Blog Post (click on image below)
What is Public Health Genomics? A Day in the Invisible Life of Public Health Genomics.
Friday, June 03, 2011
Genomics|Update|Current
Does it run in the family? Toolkit will soon be available at federal health centers nationwide
, Genetic Alliance, June 2New Blog Post (click on image below)
What is Public Health Genomics? A Day in the Invisible Life of Public Health Genomics.
Search Results - 'lmp ovarian' 'borderline ovarian' 2011 ASCO abstract
Find EXACT phrase: lmp ovarian
Found 1 document.
A multivariate longitudinal algorithm for early detection of ovarian cancer using multiple biomarker
---------------------------------------------------------------
Find EXACT phrase: borderline ovarian
Found 2 documents, showing 1 - 2
- Regulation of the tumor suppressor gene PAEP in the transition from serous borderline ovarian tumors to low-grade serous ovarian carcinomas. | 2011 ASCO Annual Meeting Abstracts
... from serous borderline ovarian tumors to low-grade serous ovarian carcinomas. | 2011 ASCO ...
... Background: Serous borderline ovarian tumors (SBOT) and low grade serous ovarian carcinomas (LG) ...
- Elevation
of HE4 and CA 125 in symptomatic patients with invasive epithelial
ovarian cancer. | 2011 ASCO Annual Meeting Abstracts
... were malignant. Borderline ovarian tumors were excluded from the analyses. A total of 115 cases ...
Search Results: gynae/gynecologic oncologist - 2011 ASCO Abstracts
No documents found relating to your query/s.
Find EXACT phrase: gynecologic oncologist
Find EXACT phrase: gynaecologic oncologist
Mutational analysis and clinical correlation of 185 consecutive metastatic colorectal patients: Similarities and differences between colon and rectal patients| 2011 ASCO Abstract
Conclusions:
Rectal and colon patients have similar rates of KRAS and PIK3CA mutations. However, BRAF mutations are more common in colon cancer. NRAS mutations are exclusively found in rectosigmoid cancers and may have a different biology than other colorectal cancers. These data suggest that primary tumor location may provide a means to enrich a population for a genotype-directed study.
Thursday, June 02, 2011
Search Results: palliative vs hospice 2011 ASCO Abstractsts
Find ALL words: palliative vs hospice
Found 35 documents, showing
Search Results: clear cell ovarian | 2011 ASCO abstracts
Note: search term of 'clear cell' resulted in numerous renal clear cell abstracts
Search
| No documents found relating to your query. |
Find EXACT phrase: clear cell ovarian
Search Results "ovarian cancer" | 2011 ASCO Annual Meeting Abstracts
Find EXACT phrase: ovarian cancer
Found 246 documents
University of Pennsylvania School of Medicine - Women with BRCA mutations can take hormone-replacement therapy safely after ovary removal
CHICAGO) ––
Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology's annual meeting (Abstract #1501). Results of the prospective study indicated that women with BRCA mutations who had their ovaries removed and took short-term HRT had a decrease in the risk of developing breast cancer...............
Domchek says some of the confusion about the role of HRT in cancer risk elevation comes from the fact that the risks and benefits associated with HRT depend on the population of women studied. In this group of women – who have BRCA1/2 mutations and who have had their ovaries removed while they are quite young – HRT should be discussed and considered an option for treating menopausal symptoms. "People want to make hormone replacement therapy evil, so they can say 'Don't do it,'" she says. "But there isn't one simple answer. The devil is in the details of the studies."
By contrast, Penn researchers and their collaborators in the PROSE consortium have shown definitively that oophorectomy reduces ovarian and breast cancer incidence in these women, and reduces their mortality due to those cancers. But paying attention to the role that hormone depletion following preventive oophorectomy plays in women's future health (blogger's note: eg. cardiovascular) is also important............"
press release: Pfizer Licenses PARP Inhibitor To Clovis Oncology (PF-01367338)
"...PF-01367338 would be developed by Clovis as both a monotherapy and in combination with chemotherapeutic agents for the potential treatment of selected cancer patients.
PF-01367338 is currently in a Phase 1 clinical trial examining the maximum tolerated dose of oral PF-01367338 that can be combined with intravenous platinum chemotherapy in the treatment of solid tumors.
Clovis was founded by former executives of Pharmion Corp., which was acquired by Celgene Corporation in 2008. The company is headquartered in Boulder, Colorado, and has additional offices in San Francisco and London."
Medical News: Group Issues Gyn Cancer Follow-Up Guidance - MedPage Today
For ovarian (epithelial) cancer, the committee recommended:
- Physical exam and review of symptoms: Every three months for two years, followed by increasing intervals
- Pap test: Not indicated
- CA-125: Optional
- Radiographic imaging: Insufficient data to support routine use
- Suspected recurrence: CT and/or PET, plus CA-125
- Physical exam and review of symptoms: Every two to four months for two years, then every six months or annually depending on histology
- Serum tumor markers: Every two to four months for two years, then every six months for sex-cord stromal tumors but no longer indicated for germ-cell tumors
- Radiographic imaging: Generally, not indicated or data lacking to support routine use
- Suspected recurrence: CT and tumor markers
Moreover, a survey of primary care providers showed that respondents believed transition of oncology patients could be improved with individualized patient summaries, guidelines for surveillance, and expedited referral for suspected recurrence, the committee members noted.
"Thus, the provision of up-to-date information and the education of both patients and physicians are mandatory," they wrote.
"Action Points
Point out that this report indicates that there is very little evidence that either routine cytologic procedures or imaging are sufficiently useful to detect ovarian and endometrial cancer recurrence and alter response rates to salvage therapy.
Note that this report suggests that the most effective method to detect recurrences is a taking a thorough history, performing a detailed physical examination, and educating patients about relevant symptoms."
SGO sets new standards to monitor recurrence of gynecologic cancer more effectively
"The article is “Post treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology recommendations: by Ritu Salani, MD, MBA; Floor J. Backes, MD; Michael Fung Kee Fung, MB, BS; Christine H. Holschneider, MD; Lynn P. Parker, MD; Robert E. Bristow, MD, MBA; and Barbara A. Goff, MD (doi: 10.1016/j.ajog.2011.03.008). It will appear in the American Journal of Obstetrics & Gynecology, Volume 204, Issue 6 (June 2011) published by Elsevier."
Tuesday, May 31, 2011
Patient Page: BRCA Genes and Breast Cancer — JAMA
PROGNOSIS With screening mammograms and breast MRIs, timely treatment, and/or prophylactic surgery, the life expectancy in BRCA carriers approaches the life span of noncarriers.
Editorial/link to paper: The Use and Misuse of ICU Telemedicine — JAMA
"....A large, multicenter study published recently showed no demonstrable clinical benefit, 4 and a recent meta-analysis found no beneficial association between ICU telemedicine and in-hospital mortality. 5 These results have left clinicians, hospital administrators, and policy makers wondering how to best use this technology, if at all."
extract only: A New Frontier in Patient Safety - McCannon and Berwick — JAMA Partnership for Patients
Note: this is a pay-per-view article ($$$)
Comparison of Effect Sizes Associated With Biomarkers Reported in Highly Cited Individual Articles and in Subsequent Meta-analyses — JAMA
Context Many biomarkers are proposed in highly cited studies as determinants of disease risk, prognosis, or response to treatment,
but few eventually transform clinical practice.
Objective To examine
whether the magnitude of the effect sizes of biomarkers proposed in
highly cited studies is accurate or overestimated.................
Conclusion Highly cited biomarker studies often report larger effect estimates for postulated associations than are reported in subsequent
meta-analyses evaluating the same associations.
press release - UK - Targeted testing offers treatment hope for ovarian cancer patients
Public release date: 30-May-2011
Targeted testing offers treatment hope for ovarian cancer patients
Women with ovarian cancer could be helped by a new test that identifies the specific type of tumour they have, a conference will hear this week.
Researchers at the University of Edinburgh hope this improved diagnosis will help doctors to personalise treatment programmes so that patients receive the most effective drugs.
The Edinburgh team worked with scientists from Ireland to identify six subgroups of the disease, each of which had a different genetic signature.
To do this, they analysed tissue samples from more than 350 ovarian cancer patients and compared this information with the patients' medical records.
The results show how genetic profiling of ovarian cancers might predict a person's response to drug treatments.
Researchers say the development may be particularly helpful for women with an aggressive form of ovarian cancer, which is typically caught late by current diagnostic tests.
This type of aggressive – or 'high grade' – cancer can respond well to a recently-developed drug that targets the blood supply of the cancer cells. (blogger's note - it is not clear from this press release if this is specific to serous cell type)
The team hopes that by identifying the women with this type of cancer at the earliest opportunity, they could use the drug more effectively and help to improve survival rates.
The findings will be presented at the American Society of Clinical Oncology (ASCO) conference, being held in Chicago this week.
Dr Charlie Gourley of the University of Edinburgh, who led the study, said: "This research shows that by conducting a detailed analysis of the genes of ovarian cancers we may be able to identify those patients who will respond well to new drug treatments. This could bring valuable improvements in survival rates for the disease and would help us to personalise a patient's care to ensure the greatest possible success."
Ovarian cancer is the fifth most common cancer in women, with around 6,800 women being diagnosed every year in the UK.
Of these, nearly two-thirds will not live beyond five years of their diagnosis.
Chemotherapy and surgery can be effective treatments, but women could have a greater chance of surviving the disease if it is identified earlier on.
The findings will be presented at ASCO on Saturday 4th June.
Initiatives and Resources | Psychosocial Oncology Education Opportunities Directory | Cancer View Canada
Note:
this program includes providers, volunteers and students but does not include patients/families/caregivers------------------------------------------------------------------
Psychosocial Oncology Education Opportunities Directory
This directory connects you with information relating to psychosocial oncology education opportunities available throughout Canada.
These include:
• courses
• field/clinical placements and field/clinical training opportunities
• research training opportunities
• other opportunities such as conferences, workshops, retreats
Canadian Cancer Statistics 2011
Canada - Ovary - incidence 2,600
Canada - Ovary - deaths 1,750
est. 5 yr survival rate ovarian cancer (all stages) 42%
est. 5 yr survival rate breast cancer 88%
* see table 2.2 for provincial stats
* see table 6 for lifetime probability of developing and dying from
ovarian cancer (1 in 69 ; 1 in 92)
(important note regarding stats - to put this in perspective, overall incident rates of ovarian cancer is relatively low (2,600 est. women annually/national basis) as a comparison to other cancers, however, as we know there still is no early detection test)
Monday, May 30, 2011
press release: OVARIAN CANCER (in) CANADA | Harris Decima survey shows Canadian women more aware of ovarian cancer (not so fast...)
Note: poorly written press release or; was it the survey? the question/s ? the design?
Blogger's keypoints - in matters of full transparency:
* where are the results of the full survey?
* demographics of repondents ?
the prior survey done in 2005 was not made available to the public either - yet funded with public/survivour funding
2) Canada's population est = 2011 - 34,409,066
Blogger's Note: No explanation on the 51 years? exactly 51 years of age ?
"Other key study findings include:
- Awareness of ovarian cancer as a potentially fatal disease has increased (71% vs. 65%), particularly among women 51 years and older, who are at a greater risk of being diagnosed with ovarian cancer (71% vs. 58%)"
Subscribe to:
Posts
(
Atom
)
